"This drug and all the others are not cures for the disease," Doody said. "This is promising … but it's not marketed anywhere in the world right now, and it hasn't been approved in any country."
Doody and her team are recruiting for a six month, Phase III FDA trial in the U.S., Europe and South America. The results of that trial will determine whether Diebon moves on to the the FDA drug approval process.
Do you have more information about this topic? If so, please click here to contact the editors of ABC News.
